Company · one vision

About OnKommon

We exist so that no treatment option is missed because the science was too complex, too scattered, or too expensive to reach.

Why we exist

One vision

Because every life deserves every option.

We exist so that no treatment option is missed because the science was too complex, too scattered, or too expensive to reach.

Our long-term vision is a computational digital twin of every patient’s cancer: a living model in which every therapy can be explored before it is ever given. Everything we do today is a step toward that, and useful care in its own right along the way.

Photograph to come

The OnKommon team in New Delhi

Ratio16/9

Shot briefLaunch blocker

Group portrait of the actual team in the actual workspace. Not a boardroom, not stock. Mixed scientific and care staff together, because the point of the company is that those two halves are one service.

Environmental group portrait in the real workspace. Wide, natural light, eye level.

Must be in frame

The actual team in the actual office
Scientific and care staff together in one frame
Names and roles captioned beneath the image

Must not be

A boardroom table, a stock office, or a hired crowd
Anyone not currently employed by OnKommon

Draft alt text: The OnKommon team photographed together in their workspace, scientific and care staff side by side.
Consent and rights: Written release from every identifiable person, plus site permission from the facility. Nothing filmed in a clinical area while real patients are present.

Before launch: Save the supplied photograph as assets/img/team-onkommon.jpg and rebuild. The brief above is replaced automatically once the file is present.

The gap we were built to close

Comprehensive genomic testing has arrived. But for most patients the result is a dense report with no decision attached, no plan, and no one to help act on it. Often in a language they do not fully understand, recommending drugs they cannot afford.

Data to decision

We turn a variant list into a ranked, signed plan.

Decision to access

We map biosimilars, assistance programmes and schemes.

Access to action

A named navigator carries the plan into real life.

Two halves of one whole

OnKommon is the product, the intelligence and the technology. KPCIRC, our exclusive clinical partner, is the licensed clinical authority: tumour boards, sign-offs, second opinions, genetic counselling and patient navigation.

A licensed clinician is accountable. No machine decides.

OnKommon was born inside KPCIRC, the Kwatra Precision Cancer Institute and Research Centre, and remains in exclusive partnership with it. That origin is why our intelligence arrives wrapped in genuine clinical care rather than sold as software.

How we fit into your care

Your teamYour oncologist leads
They make the clinical decisions.
OnKommonWe read the tumour
And turn the data into a ranked, evidenced plan.
KPCIRCA tumour board signs
Licensed clinicians review, author and take responsibility.
YouYou receive the plan
With a regional-language summary and a navigator.

Accredited to recognised standards

The laboratory work behind every report is held to Indian and international standards. Each accreditation below covers something different.

NABL

ISO 15189

National Accreditation Board for Testing and Calibration Laboratories, the Indian accreditation for medical testing laboratories, assessed against ISO 15189.

CAP

College of American Pathologists

Accreditation covering laboratory quality management, proficiency testing and inspection on a two-year cycle.

CLIA

Clinical Laboratory Improvement Amendments

The United States standard for laboratory testing on human samples.

ISO 15189

Medical laboratory quality

The international standard for quality and competence in medical laboratories.

ISO 9001

Quality management

Quality management systems across the wider operation, not only the bench.

CE-IVD

Certified variant database

Variant classification and reporting run against a CE-marked in-vitro diagnostic database.

Sequencing and variant calling are performed by our accredited laboratory partner. Accreditation covers the laboratory work: the OnKommon interpretation engine is separately provided for research and decision-support use, and clinical authority rests with KPCIRC.

Where OnKommon came from

Born inside KPCIRC

We did not start in a laboratory looking for a market. We started in a clinic, with a problem.

OnKommon was built inside the Kwatra Precision Cancer Institute and Research Centre, from a recurring problem its clinicians could see every week: reports arriving that no one had time to turn into a decision, families holding paperwork they could not read, and options that existed but were never reached.

That origin decides how the company is shaped. The technology sits with OnKommon. The clinical authority sits with KPCIRC, where it belongs, and every clinically consequential statement we publish is authored and signed there by licensed clinicians. It is why our reports are signed by people who also see patients, and why the molecular tumour board that reviews your case is a real standing board rather than a name on a page.

Built from a clinical problem

The service exists because clinicians kept hitting the same wall, not because a technology needed an application.

Clinical authority stays clinical

KPCIRC signs. OnKommon builds the engine, the report and the navigation around it.

One standing tumour board

The same board that reviews KPCIRC cases reviews ours. It is not assembled per case.

Clinicians reviewing a case together at a molecular tumour board meeting. — The board that signs an OnKommon report is the board that already meets at KPCIRC.

Where we are

OnKommon operates from New Delhi. Wherever you are in the country, care is coordinated remotely by your named navigator, with sampling arranged locally.

New Delhiour base

Pan-Indiasampling coordinated locally

Regionallanguages for every summary

Take the next step